论文部分内容阅读
目的 :系统评价国内有关乳腺癌组织中血管内皮生长因子-D(VEGF-D)表达与临床意义的关系。方法:检索CNKI、pubmedCBM和万方数据库并辅以文献追溯的方法,收集公开发表的有关乳腺癌组织中VEGF-D表达及其与临床意义的病例对照研究。检索年限均从2002年~2012年。按纳入排除标准筛选文献并评价纳入研究质量后,应用RevMan5.0软件进行Meta分析。结果:共纳入11个病例对照研究。Meta分析结果显示:VEGF-D在乳腺癌淋巴结转移阳性组和阴性组[OR=2.26,95%CI(1.75,2.92)]及乳腺癌1-2期组和≥3期组[OR=0.45,95%C(I0.24,0.86)]之间的表达有统计学意义,而在≤50岁组和>50岁组[OR=1.02,95%C(I0.73,1.42)],组织学1~2级组与3级组[OR=1.21,95%C(I0.83,1.78)]和肿瘤大小≤2 cm组与>2 cm组[OR=1.23,95%C(I0.88,1.74)]之间的表达无统计学意义。结论:目前国内外证据证明,VEGF-D可能参与乳腺癌淋巴结转移等发生发展等的过程,并可能成为乳腺癌预后的重要因素。
OBJECTIVE: To systematically evaluate the relationship between the expression of vascular endothelial growth factor-D (VEGF-D) and clinical significance in breast cancer tissues in China. Methods: CNKI, PubMedCBM and Wanfang database were searched with literature retrospectively to collect published published case-control studies on the expression of VEGF-D in breast cancer and its clinical significance. The retrieval years are from 2002 to 2012. After selecting the inclusion criteria for inclusion and evaluating the quality of the included study, a Meta-analysis was performed using RevMan 5.0 software. Results: A total of 11 case-control studies were included. The results of Meta analysis showed that VEGF-D was significantly higher in patients with lymph node metastasis of breast cancer (OR = 2.26,95% CI 1.75,2.92) 95% C (I0.24,0.86)], while in the group of ≤50 years old and> 50 years old [OR = 1.02,95% C (I0.73,1.42)], histology OR = 1.21, 95% C (I0.83, 1.78)], tumor size ≤2 cm group and> 2 cm group [OR = 1.23,95% C (I0.88, 1.74)] between the expression was not statistically significant. Conclusion: At home and abroad, evidence suggests that VEGF-D may be involved in the development of lymph node metastasis in breast cancer and may be an important factor in the prognosis of breast cancer.